ECSP21079422A - Método para preparar formulaciones de péptidos estables - Google Patents
Método para preparar formulaciones de péptidos establesInfo
- Publication number
- ECSP21079422A ECSP21079422A ECSENADI202179422A ECDI202179422A ECSP21079422A EC SP21079422 A ECSP21079422 A EC SP21079422A EC SENADI202179422 A ECSENADI202179422 A EC SENADI202179422A EC DI202179422 A ECDI202179422 A EC DI202179422A EC SP21079422 A ECSP21079422 A EC SP21079422A
- Authority
- EC
- Ecuador
- Prior art keywords
- preparing stable
- peptide formulations
- stable peptide
- preparing
- powder formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000843 powder Substances 0.000 abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método mejorado para preparar una formulación en polvo que contiene un péptido. La presente invención también proporciona un método mejorado para preparar una formulación en polvo que contiene glucagón o un análogo de glucagón, en donde dicha formulación en polvo es adecuada para administración nasal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839246P | 2019-04-26 | 2019-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21079422A true ECSP21079422A (es) | 2021-11-30 |
Family
ID=70554273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202179422A ECSP21079422A (es) | 2019-04-26 | 2021-10-26 | Método para preparar formulaciones de péptidos estables |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220192988A1 (es) |
| EP (1) | EP3958838A1 (es) |
| JP (2) | JP7245926B2 (es) |
| KR (1) | KR20210143253A (es) |
| CN (1) | CN113727700A (es) |
| AR (1) | AR118690A1 (es) |
| AU (1) | AU2020261941B2 (es) |
| BR (1) | BR112021018325A2 (es) |
| CA (1) | CA3134757A1 (es) |
| CL (1) | CL2021002690A1 (es) |
| CO (1) | CO2021014034A2 (es) |
| EA (1) | EA202192475A1 (es) |
| EC (1) | ECSP21079422A (es) |
| IL (1) | IL286426A (es) |
| MA (1) | MA55757A (es) |
| MX (1) | MX2021012852A (es) |
| PE (1) | PE20212368A1 (es) |
| SG (1) | SG11202110413YA (es) |
| TW (1) | TWI771669B (es) |
| WO (1) | WO2020219391A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116718762A (zh) * | 2023-06-09 | 2023-09-08 | 上海品峰医疗科技有限公司 | 一种多肽类样本稳定剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| US7118675B2 (en) * | 2002-02-04 | 2006-10-10 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| US8680049B2 (en) | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| US20130053310A1 (en) | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EA201291234A1 (ru) | 2010-06-24 | 2013-07-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| MX2013015168A (es) | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
| MX2014007120A (es) | 2011-12-23 | 2015-03-05 | Boehringer Ingelheim Int | Analogos de glucagon. |
| FI124134B (en) | 2012-07-02 | 2014-03-31 | One Way Sport Oy | Binding between a ski and a ski boot |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9018162B2 (en) * | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| PE20171334A1 (es) * | 2015-02-17 | 2017-09-13 | Lilly Co Eli | Formulacion en polvo nasal para el tratamiento de hipoglicemia |
-
2020
- 2020-04-14 TW TW109112446A patent/TWI771669B/zh active
- 2020-04-15 AR ARP200101057A patent/AR118690A1/es unknown
- 2020-04-20 MX MX2021012852A patent/MX2021012852A/es unknown
- 2020-04-20 WO PCT/US2020/028988 patent/WO2020219391A1/en unknown
- 2020-04-20 KR KR1020217034137A patent/KR20210143253A/ko not_active Application Discontinuation
- 2020-04-20 EP EP20724361.9A patent/EP3958838A1/en active Pending
- 2020-04-20 PE PE2021001736A patent/PE20212368A1/es unknown
- 2020-04-20 US US17/606,214 patent/US20220192988A1/en active Pending
- 2020-04-20 EA EA202192475A patent/EA202192475A1/ru unknown
- 2020-04-20 CA CA3134757A patent/CA3134757A1/en active Pending
- 2020-04-20 SG SG11202110413YA patent/SG11202110413YA/en unknown
- 2020-04-20 BR BR112021018325A patent/BR112021018325A2/pt unknown
- 2020-04-20 JP JP2021560275A patent/JP7245926B2/ja active Active
- 2020-04-20 MA MA055757A patent/MA55757A/fr unknown
- 2020-04-20 AU AU2020261941A patent/AU2020261941B2/en active Active
- 2020-04-20 CN CN202080027937.1A patent/CN113727700A/zh active Pending
-
2021
- 2021-09-14 IL IL286426A patent/IL286426A/en unknown
- 2021-10-14 CL CL2021002690A patent/CL2021002690A1/es unknown
- 2021-10-20 CO CONC2021/0014034A patent/CO2021014034A2/es unknown
- 2021-10-26 EC ECSENADI202179422A patent/ECSP21079422A/es unknown
-
2023
- 2023-03-13 JP JP2023038306A patent/JP2023075249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021014034A2 (es) | 2021-10-29 |
| IL286426A (en) | 2021-10-31 |
| KR20210143253A (ko) | 2021-11-26 |
| SG11202110413YA (en) | 2021-10-28 |
| MA55757A (fr) | 2022-03-02 |
| CL2021002690A1 (es) | 2022-07-08 |
| MX2021012852A (es) | 2021-12-10 |
| WO2020219391A1 (en) | 2020-10-29 |
| EA202192475A1 (ru) | 2022-01-28 |
| TW202108599A (zh) | 2021-03-01 |
| AU2020261941B2 (en) | 2023-04-06 |
| JP2023075249A (ja) | 2023-05-30 |
| CN113727700A (zh) | 2021-11-30 |
| EP3958838A1 (en) | 2022-03-02 |
| AR118690A1 (es) | 2021-10-27 |
| BR112021018325A2 (pt) | 2021-11-23 |
| JP2022529614A (ja) | 2022-06-23 |
| TWI771669B (zh) | 2022-07-21 |
| PE20212368A1 (es) | 2021-12-21 |
| JP7245926B2 (ja) | 2023-03-24 |
| CA3134757A1 (en) | 2020-10-29 |
| AU2020261941A1 (en) | 2021-10-14 |
| US20220192988A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| SV2017005515A (es) | Formulaciones de polvo nasal para el tratamiento de la hipoglicemia | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
| WO2019087083A3 (en) | Oral delivery of glp-1 peptide analogs | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| MX2021006969A (es) | Ligante peptidico. | |
| PH12018502615A1 (en) | Depot formulations | |
| CU20210077A7 (es) | Extractos bacterianos estables como fármacos | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| ECSP21060917A (es) | Formulación de anticuerpos terapéuticos | |
| ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
| AU2017370226A1 (en) | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof | |
| CL2022001486A1 (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| MX2020010085A (es) | Formulaciones que contienen péptidos. | |
| MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
| CL2022001085A1 (es) | Formulación de anticuerpo que contiene crizanlizumab | |
| MX2020010928A (es) | Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea. | |
| EA202191327A1 (ru) | Лекарственные формы терапевтических препаратов от гриппа | |
| EA202092373A1 (ru) | Сухая порошкообразная фармацевтическая композиция для ингаляции, содержащая тиреоидный гормон | |
| BR112021026575A2 (pt) | Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1 |